PMID- 28420715
OWN - NLM
STAT- MEDLINE
DCOM- 20180323
LR  - 20220410
IS  - 1479-6813 (Electronic)
IS  - 0952-5041 (Linking)
VI  - 59
IP  - 1
DP  - 2017 Jul
TI  - Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic 
      nephropathy.
PG  - R1-R10
LID - 10.1530/JME-17-0005 [doi]
AB  - Diabetic nephropathy is one of the most frequent, devastating and costly 
      complications of diabetes. The available therapeutic approaches are limited. 
      Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of 
      glucose-lowering drugs that might also have reno-protective properties. DPP-4 
      exists in two forms: a plasma membrane-bound form and a soluble form, and can 
      exert many biological actions mainly through its peptidase activity and 
      interaction with extracellular matrix components. The kidneys have the highest 
      DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are 
      up-regulated in diabetic nephropathy, highlighting its role as a potential target 
      to manage diabetic nephropathy. Preclinical animal studies and some clinical data 
      suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in 
      a blood pressure- and glucose-independent manner. Many studies reported that 
      these reno-protective effects could be due to increased half-life of DPP-4 
      substrates such as glucagon-like peptide-1 (GLP-1) and stromal derived factor-1 
      alpha (SDF-1a). However, the underlying mechanisms are far from being completely 
      understood and clearly need further investigations.
CI  - (c) 2017 Society for Endocrinology.
FAU - Hasan, Ahmed A
AU  - Hasan AA
AD  - Institute of Nutritional ScienceUniversity of Potsdam, Potsdam, Germany.
AD  - Department of BiochemistryFaculty of Pharmacy, Zagazig University, Zagazig, 
      Egypt.
FAU - Hocher, Berthold
AU  - Hocher B
AD  - Institute of Nutritional ScienceUniversity of Potsdam, Potsdam, Germany 
      hocher@uni-potsdam.de.
AD  - Institut fur Laboriatorumsmedizin IFLbBerlin, Germany.
AD  - Departments of Embryology and NephrologyBasic Medical College, Jinan University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170418
PL  - England
TA  - J Mol Endocrinol
JT  - Journal of molecular endocrinology
JID - 8902617
RN  - 0 (CXCL12 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Protective Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Animals
MH  - Chemokine CXCL12/agonists/genetics/metabolism
MH  - Clinical Trials as Topic
MH  - Diabetic Nephropathies/*drug therapy/enzymology/genetics/pathology
MH  - Dipeptidyl Peptidase 4/*genetics/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Drug Evaluation, Preclinical
MH  - Extracellular Matrix
MH  - Gene Expression Regulation
MH  - Glucagon-Like Peptide 1/agonists/genetics/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Mesangial Cells/*drug effects/enzymology/pathology
MH  - Podocytes/*drug effects/enzymology/pathology
MH  - Protective Agents/*therapeutic use
OTO - NOTNLM
OT  - DPP-4
OT  - DPP-4 inhibitors
OT  - GLP-1 and SDF-1a
OT  - diabetic nephropathy
EDAT- 2017/04/20 06:00
MHDA- 2018/03/24 06:00
CRDT- 2017/04/20 06:00
PHST- 2017/03/17 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/04/20 06:00 [pubmed]
PHST- 2018/03/24 06:00 [medline]
PHST- 2017/04/20 06:00 [entrez]
AID - JME-17-0005 [pii]
AID - 10.1530/JME-17-0005 [doi]
PST - ppublish
SO  - J Mol Endocrinol. 2017 Jul;59(1):R1-R10. doi: 10.1530/JME-17-0005. Epub 2017 Apr 
      18.